Free Trial

Cardlytics (NASDAQ:CDLX) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Cardlytics logo with Business Services background

Cardlytics (NASDAQ:CDLX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.18, Briefing.com reports. Cardlytics had a negative return on equity of 93.64% and a negative net margin of 93.55%. The business had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. During the same period in the previous year, the company posted ($0.26) EPS. Cardlytics's revenue was down 15.1% on a year-over-year basis. Cardlytics updated its Q4 2024 guidance to EPS.

Cardlytics Price Performance

Shares of Cardlytics stock traded up $0.30 on Friday, hitting $4.37. The company's stock had a trading volume of 1,752,101 shares, compared to its average volume of 726,140. The company has a market capitalization of $222.09 million, a price-to-earnings ratio of -0.72 and a beta of 1.61. The firm has a fifty day moving average price of $3.69 and a 200-day moving average price of $6.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.77 and a current ratio of 1.77. Cardlytics has a 1 year low of $2.89 and a 1 year high of $20.52.

Insider Activity

In related news, Director Scott A. Hill acquired 40,000 shares of Cardlytics stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the transaction, the director now owns 40,000 shares of the company's stock, valued at approximately $143,200. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Scott A. Hill acquired 40,000 shares of the business's stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $3.58 per share, for a total transaction of $143,200.00. Following the purchase, the director now owns 40,000 shares in the company, valued at approximately $143,200. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the sale, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,573 shares of company stock worth $151,612 over the last three months. 4.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Northland Securities cut shares of Cardlytics from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $7.00 to $5.00 in a research note on Friday, August 16th. Evercore ISI initiated coverage on Cardlytics in a research note on Friday, October 11th. They issued an "in-line" rating and a $4.00 target price for the company. Craig Hallum raised Cardlytics from a "hold" rating to a "strong-buy" rating in a report on Wednesday. Northland Capmk lowered shares of Cardlytics from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 16th. Finally, Lake Street Capital cut shares of Cardlytics from a "buy" rating to a "hold" rating and reduced their target price for the stock from $18.00 to $5.00 in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Cardlytics presently has a consensus rating of "Hold" and a consensus price target of $6.92.

Get Our Latest Analysis on CDLX

About Cardlytics

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Stories

Earnings History for Cardlytics (NASDAQ:CDLX)

→ Trump won. Buy this coin now. (From Weiss Ratings) (Ad)

Should you invest $1,000 in Cardlytics right now?

Before you consider Cardlytics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardlytics wasn't on the list.

While Cardlytics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?
These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines